- Home
- MIRA vs BIVI Comparison
MIRA vs BIVI Comparison
Compare MIRA & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- BIVI
- Stock Information
- Founded
- MIRA 2020
- BIVI 2013
- Country
- MIRA United States
- BIVI United States
- Employees
- MIRA N/A
- BIVI N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- BIVI Health Care
- Exchange
- MIRA Nasdaq
- BIVI Nasdaq
- Market Cap
- MIRA 19.5M
- BIVI 18.6M
- IPO Year
- MIRA 2023
- BIVI N/A
- Fundamental
- Price
- MIRA $1.25
- BIVI $1.02
- Analyst Decision
- MIRA Strong Buy
- BIVI Strong Buy
- Analyst Count
- MIRA 2
- BIVI 1
- Target Price
- MIRA $14.00
- BIVI $30.00
- AVG Volume (30 Days)
- MIRA 168.5K
- BIVI 194.8K
- Earning Date
- MIRA 08-12-2025
- BIVI 05-12-2025
- Dividend Yield
- MIRA N/A
- BIVI N/A
- EPS Growth
- MIRA N/A
- BIVI N/A
- EPS
- MIRA N/A
- BIVI N/A
- Revenue
- MIRA N/A
- BIVI N/A
- Revenue This Year
- MIRA N/A
- BIVI N/A
- Revenue Next Year
- MIRA N/A
- BIVI N/A
- P/E Ratio
- MIRA N/A
- BIVI N/A
- Revenue Growth
- MIRA N/A
- BIVI N/A
- 52 Week Low
- MIRA $0.51
- BIVI $0.62
- 52 Week High
- MIRA $5.01
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- MIRA 46.62
- BIVI 47.95
- Support Level
- MIRA $1.15
- BIVI $1.00
- Resistance Level
- MIRA $1.30
- BIVI $1.09
- Average True Range (ATR)
- MIRA 0.08
- BIVI 0.07
- MACD
- MIRA -0.01
- BIVI -0.01
- Stochastic Oscillator
- MIRA 21.43
- BIVI 19.05
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.